Vivimed Labs Hits Lower Circuit Amid Heavy Selling Pressure

Market Performance and Price Action

On the trading day, Vivimed Labs (Stock ID: 612893) closed at ₹18.60, down ₹0.97 from the previous close, triggering the maximum permissible daily loss of 5%. This decline was notably sharper than the Pharmaceuticals & Drugs sector’s modest fall of 0.16% and the Sensex’s near-flat movement of -0.02%. The stock’s price band was set at ₹5, and it traded exclusively at the lower circuit price, indicating a complete absorption of selling interest at this level.

The stock’s intraday high and low were both ₹18.60, reflecting the circuit filter’s effect in halting further declines. Total traded volume was negligible at just 0.00014 lakh shares, with turnover amounting to a mere ₹2,604, underscoring a lack of buying interest to absorb the heavy supply. This unfilled supply and absence of counterparty demand exacerbated the downward momentum.

Investor Sentiment and Trading Dynamics

Investor sentiment towards Vivimed Labs has deteriorated sharply over recent sessions. The stock has recorded a consecutive five-day losing streak, shedding 22.53% in that period. Despite the stock price remaining above its 20-day, 50-day, 100-day, and 200-day moving averages, it has slipped below the 5-day moving average, signalling short-term bearishness. This divergence suggests that while longer-term trends may still hold some support, immediate market pressures are overwhelming.

Delivery volume on 29 Dec surged to 7,690 shares, a 105.46% increase compared to the five-day average, indicating rising investor participation but predominantly on the sell side. The spike in delivery volume alongside falling prices points to panic selling, with shareholders offloading positions amid fears of further declines.

Market Capitalisation and Quality Assessment

Vivimed Labs is classified as a micro-cap company with a market capitalisation of ₹162 crore. Its Mojo Score stands at a low 24.0, accompanied by a Strong Sell Mojo Grade as of 22 Dec 2025, reflecting deteriorated fundamentals and weak market sentiment. The downgrade from a previously ungraded status highlights growing concerns among analysts and market participants regarding the company’s near-term prospects.

Sector Comparison and Relative Underperformance

Vivimed Labs’ underperformance relative to its sector peers is stark. While the Pharmaceuticals & Drugs sector has remained relatively stable, the stock’s 4.96% fall on 30 Dec 2025 highlights its vulnerability amid broader market resilience. This divergence may be attributed to company-specific concerns, including weak earnings outlook, operational challenges, or negative news flow that has not impacted the sector at large.

Investors should note that the stock’s liquidity remains limited, with average traded value representing only 2% of the five-day average, restricting the ability to execute large trades without impacting price. This illiquidity can amplify price swings and contribute to volatility, especially during periods of panic selling.

Technical Indicators and Moving Averages

Technically, Vivimed Labs is at a critical juncture. The stock’s price is currently below its short-term 5-day moving average but remains above longer-term averages, suggesting a potential support zone. However, the persistent downward pressure and circuit hit indicate that immediate recovery is unlikely without a catalyst.

Investors should monitor volume trends closely. The recent spike in delivery volume coupled with falling prices is a bearish signal, often indicative of sustained selling interest. Unless buying demand returns to absorb the excess supply, the stock may continue to face downward pressure.

Outlook and Analyst Recommendations

Given the current market dynamics and the company’s deteriorated Mojo Grade of Strong Sell, analysts remain cautious on Vivimed Labs. The downgrade on 22 Dec 2025 reflects concerns over the company’s fundamentals and market positioning. Investors are advised to exercise prudence and consider alternative investment opportunities with stronger momentum and better risk-reward profiles.

Investor Takeaway

Vivimed Labs’ recent plunge to its lower circuit price limit underscores the intense selling pressure and panic among shareholders. The stock’s new 52-week low at ₹18.60, combined with a strong sell rating and weak market metrics, signals caution for investors. While the micro-cap status and limited liquidity add to volatility risks, the absence of meaningful buying interest suggests that the stock may remain under pressure in the near term.

Investors should closely monitor any developments related to the company’s operational performance, sector trends, and broader market conditions before considering fresh exposure. Diversifying into stocks with stronger momentum and more favourable fundamentals may be a prudent strategy in the current environment.

Summary

In summary, Vivimed Labs’ stock performance on 30 Dec 2025 was marked by a maximum daily loss of 4.96%, hitting the lower circuit price of ₹18.60. The stock’s underperformance relative to its sector and the Sensex, combined with rising delivery volumes and unfilled supply, highlights a scenario of panic selling and bearish sentiment. The company’s Strong Sell Mojo Grade and micro-cap status further reinforce the need for caution among investors.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →